Advertisement

Topics

U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

06:30 EST 10 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Sprycel is the first and only second-generation tyrosine kinase inhibitor approved for children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase Approval based on data from the largest pro...

Other Sources for this Article

Bristol-Myers Squibb Company
Media Inquiries:
Laurel Sacks, 609-302-5456
917-861-0746 (cell)
laurel.sacks@bms.com
or
Investors:
Tim Power, 609-252-7509
timothy.power@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com

NEXT ARTICLE

More From BioPortfolio on "U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...